Literature DB >> 22786897

Antibody-mediated retinal pericyte injury: implications for diabetic retinopathy.

Yan Li1, Dawn Smith, Qing Li, Nader Sheibani, Suber Huang, Timothy Kern, Ram H Nagaraj, Feng Lin.   

Abstract

PURPOSE: To test the hypothesis that autoantibodies against retinal pericytes could develop in diabetic retinopathy, and that these autoantibodies could induce retinal pericyte dysfunction/death via complement.
METHODS: Human primary retinal pericytes cultured in media containing normal (5 mM) or high (30 mM) glucose concentrations were incubated with normal human sera in the presence of a retinal pericyte-reactive antibody, then their viability was assessed by a BCECF-based cytotoxicity assay, and their function was assessed by a T-cell proliferation assay. The pericytes were also analyzed by RT-PCR and flow cytometry to detect CD38, an established diabetes-associated cell surface autoantigen. The potential of the anti-CD38 antibodies in inducing pericyte cellular injury was evaluated using the same cytotoxicity assays. In addition, autoantibody-mediated cytotoxicity in mouse retinal pericytes sensitized by sera from mice with developing diabetic retinopathy or control normal mice were also studied.
RESULTS: Retinal pericyte-reactive antibodies induced cellular damage by activating complement in the serum. The antibody-injured pericytes had reduced efficacy in inhibiting T cells. Hyperglycemic culture conditions rendered pericytes more susceptible to antibody-mediated attack. CD38 was expressed in retinal pericytes, and upregulated by TNF-α and IFN-γ, and anti-CD38 antibodies induced pericyte cytotoxicity. Retinal pericytes sensitized with sera from chronic diabetic mice suffered significantly augmented cytotoxicity compared with those sensitized with sera from the control mice.
CONCLUSIONS: The autoantibody-initiated complement activation could be a mechanism underlying the loss of function, and eventually, death of retinal pericytes in diabetic patients, suggesting that inhibiting complement activation could be a novel therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22786897      PMCID: PMC3419006          DOI: 10.1167/iovs.12-10010

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  30 in total

1.  Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes.

Authors:  F Pomero; A Allione; E Beltramo; S Buttiglieri; F D'Alù; E Ponte; A Lacaria; M Porta
Journal:  Diabetologia       Date:  2003-03-01       Impact factor: 10.122

2.  Retinal pericytes inhibit activated T cell proliferation.

Authors:  Zhidan Tu; Yan Li; Dawn S Smith; Nader Sheibani; Suber Huang; Timothy Kern; Feng Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-21       Impact factor: 4.799

3.  Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies.

Authors:  R Mallone; E Ortolan; S Pinach; M Volante; M M Zanone; G Bruno; G Baj; T Lohmann; P Cavallo-Perin; F Malavasi
Journal:  Diabetologia       Date:  2002-10-24       Impact factor: 10.122

4.  Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Authors:  Feng Lin; Henry J Kaminski; Bianca M Conti-Fine; Wei Wang; Chelliah Richmonds; M Edward Medof
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Circulating antipericyte autoantibodies in diabetic retinopathy.

Authors:  M A Attawia; R C Nayak
Journal:  Retina       Date:  1999       Impact factor: 4.256

Review 6.  The murine complement regulator Crry: new insights into the immunobiology of complement regulation.

Authors:  H Molina
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

7.  Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy.

Authors:  Jing Zhang; Chiara Gerhardinger; Mara Lorenzi
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

8.  Circulating anti-pericyte autoantibodies are present in Type 2 diabetic patients and are associated with non-proliferative retinopathy.

Authors:  R C Nayak; C D Agardh; M G K Kwok; H Stjernquist; P J Farthing-Nayak; E Agardh
Journal:  Diabetologia       Date:  2003-03-13       Impact factor: 10.122

9.  Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction.

Authors:  Ulriche Denis; Marc Lecomte; Clarisse Paget; Daniel Ruggiero; Nicolas Wiernsperger; Michel Lagarde
Journal:  Free Radic Biol Med       Date:  2002-07-15       Impact factor: 7.376

10.  Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterization.

Authors:  R Mallone; E Ortolan; G Baj; A Funaro; S Giunti; E Lillaz; F Saccucci; M Cassader; P Cavallo-Perin; F Malavasi
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

View more
  15 in total

Review 1.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

Review 2.  From pathobiology to the targeting of pericytes for the treatment of diabetic retinopathy.

Authors:  Joseph F Arboleda-Velasquez; Cammi N Valdez; Christina K Marko; Patricia A D'Amore
Journal:  Curr Diab Rep       Date:  2015-02       Impact factor: 4.810

Review 3.  New insight into the role of the complement in the most common types of retinopathy-current literature review.

Authors:  Martyna Chrzanowska; Anna Modrzejewska; Monika Modrzejewska
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

4.  Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.

Authors:  Jijun Xu; Lingjun Zhang; Mian Xie; Yan Li; Ping Huang; Thomas L Saunders; David A Fox; Richard Rosenquist; Feng Lin
Journal:  J Immunol       Date:  2018-04-25       Impact factor: 5.422

Review 5.  Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?

Authors:  Akanksha Gupta; Sonika Bhatnagar
Journal:  OMICS       Date:  2015-12

Review 6.  The innate immune system in diabetic retinopathy.

Authors:  Warren W Pan; Feng Lin; Patrice E Fort
Journal:  Prog Retin Eye Res       Date:  2021-01-08       Impact factor: 19.704

Review 7.  Diabetes and retinal vascular dysfunction.

Authors:  Eui Seok Shin; Christine M Sorenson; Nader Sheibani
Journal:  J Ophthalmic Vis Res       Date:  2014 Jul-Sep

8.  Proteasome Activators, PA28α and PA28β, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy.

Authors:  Saeed Yadranji Aghdam; Ali Mahmoudpour
Journal:  Int J Nephrol       Date:  2016-10-18

9.  Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients.

Authors:  Lingjun Zhang; Yan Li; John Payne; Sunil Srivastava; Xingjun Fan; John Fung; Xiaorong Li; Timothy S Kern; Feng Lin
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

10.  Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to Glucose.

Authors:  Michael A Grassi; Vidhya R Rao; Siquan Chen; Dingcai Cao; Xiaoyu Gao; Patricia A Cleary; R Stephanie Huang; Andrew D Paterson; Rama Natarajan; Jalees Rehman; Timothy S Kern
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.